Download the presentation here: PDF
Download the presentation here: PDF
Download the presentation here: PDF
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Good Phase III Data, An Accepted NDA … But No<br />
Commercial Partner<br />
December 19, 2008: NeurogesX Announces FDA Acceptance to Review New<br />
Drug Application for NGX-4010 to Treat Post-Herpetic Neuralgia<br />
Backonja M, et al. Presented at <strong>the</strong> American Academy of Neurology<br />
60th Annual Meeting, Chicago; April 2008<br />
85<br />
© Defined Health, 2009<br />
Pain Insight Briefing<br />
Primary endpoint (% reduction<br />
from baseline during Weeks 2-8)<br />
•NGX-4010 −32% vs. Control −24%<br />
(p=0.011)<br />
•Consistent results over 3 months<br />
•32% average pain reduction during<br />
Weeks 2-12 (p=0.0172)<br />
•Responders (≥ 30% reduction) 46%<br />
responders (p=0.0196)